{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:20:57Z","timestamp":1747149657656,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIA T-32 Training Grant","award":["T32AG000262"],"award-info":[{"award-number":["T32AG000262"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Inflammatory bowel disease (IBD) consisting of Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory conditions affecting the gastrointestinal tract. Infliximab (IFX) is a chimeric anti\u2010tumor necrosis factor antibody used to treat moderate to severe IBD. Eosinophils are commonly found in chronically inflamed tissues in IBD. Peripheral eosinophilia (PE) was previously implicated as a marker of disease severity at diagnosis. The main aim of this study was to investigate whether in IBD patients on IFX, development of PE is associated with adverse outcomes and poor IFX efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive retrospective chart review of IBD patients on IFX (January 2006 to July 2015) treated at a tertiary pediatric IBD center was performed. Data was collected at time specified points over a 24\u2009month period and included demographics, atopy, disease severity, development of PE, human antichimeric antibodies (HACA), infusion reactions, cancer, psoriasis, and loss of clinical response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred twenty\u2010one IBD patients starting IFX (67 male), mean age of 12.4\u2009years (range 4\u201322\u2009years old), met inclusion criteria. Of them, 36.3% had \u22651 PE episode (CD: 25 male, 11 female; UC: 6 male, 2 female). Mean absolute eosinophil count (AEC) did not change over time. PE was associated with clinically active disease. Among patients who developed PE, adverse outcomes were not significantly different <jats:italic>versus<\/jats:italic> those who did not have PE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In a cohort of primarily pediatric IBD patients on IFX, PE was associated with clinically active disease; however, PE was not related to increased incidence of adverse outcomes or loss of drug efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jgh3.12308","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T08:29:47Z","timestamp":1581064187000},"page":"636-641","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0172-3206","authenticated-orcid":false,"given":"Douglas","family":"Zabrowski","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology\/Nutrition University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health University of Maryland School of Medicine  Baltimore Maryland USA"},{"name":"Department of Pediatrics, Division of Cardiology University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Kader","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology\/Nutrition University of Maryland School of Medicine  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01699.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.016"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.02.047"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.07.010"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.047"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3182128512"},{"key":"e_1_2_6_8_1","first-page":"276","article-title":"Increased fecal eosinophil cationic protein in inflammatory bowel disease","volume":"40","author":"Berstad A","year":"1993","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.133"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i4.560"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e31827b7674"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/LBR.0000000000000031"},{"key":"e_1_2_6_13_1","first-page":"573","article-title":"Prevalence of peripheral eosinophilia at diagnosis in children with inflammatory bowel disease","volume":"62","author":"Sadi G","year":"2016","journal-title":"JPGN"},{"key":"e_1_2_6_14_1","first-page":"248","article-title":"Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept","volume":"21","author":"Cancelliere N","year":"2011","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker322"},{"key":"e_1_2_6_16_1","unstructured":"ImproveCareNow Physician Global Assessment. Cited March2017. Available from URL:www.improvecarenow.org\/program-details"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.4.1169"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010659803912"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.072595"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310008566"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2329-7"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21349"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000226304"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mib.0000228358.25364.8b"},{"key":"e_1_2_6_25_1","article-title":"Incidence and Paris classification of pediatric inflammatory bowel disease","author":"Muller KE","year":"2014","journal-title":"Gastroenterol. Res. Practice"}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjgh3.12308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jgh3.12308","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T16:01:33Z","timestamp":1693929693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.12308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/jgh3.12308"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.12308","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"type":"print","value":"2397-9070"},{"type":"electronic","value":"2397-9070"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"2019-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}